Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review
Nutrients · 02.11.2026 · 18 (21) · 3646
DOI: 10.3390/nu18213646 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 02.11.2026. Verfasst von Klaudia Melkis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 24 Broniewskiego Street, 71-460 Szczecin, Poland. Hauptthemen laut MEDLINE: Metabolic Syndrome, Agaricales. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pomeranian Medical University.
Abstract (Originalsprache)
Background
Edible and medicinal mushrooms contain bioactive compounds potentially relevant to metabolic syndrome (MetS).
Methods
This narrative review was based on searches of PubMed and Embase from database inception to 10 April 2026. In vitro, in silico, animal and human studies, and systematic reviews were considered. Evidence was mapped by species, preparation, evidence level and outcome, distinguishing MetS diagnostic components from related outcomes.
Results
The evidence was predominantly preclinical and addressed glucose and lipid metabolism, adiposity, inflammation, oxidative stress and gut microbiota. Human evidence was dominated by Ganoderma lucidum. The only randomized trial in participants with diagnosed MetS that assessed its diagnostic components (n = 84) found no effect of G. lucidum, alone or combined with Cordyceps sinensis, on glycemia, blood pressure, lipids, waist circumference or MetS status. Systematic reviews reported no significant effects on fasting blood glucose, blood pressure or lipid profile and a small reduction in body mass index without a corresponding change in waist circumference, although the certainty of evidence was very low. Individual, unreplicated trials reported improvements in specific components.
Conclusions
Mechanistic plausibility has not translated into demonstrated clinical efficacy. Insufficient chemical characterization and standardization of preparations preclude species-specific recommendations. Trials of standardized preparations in participants with diagnosed MetS are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Nutrition and Metabolomics, Pomeranian Medical University in Szczecin, 24 Broniewskiego Street, 71-460 Szczecin, Poland.
ORCID-Profile: Klaudia Melkis, Karolina Jakubczyk
Förderung
- Pomeranian Medical University
Zitieren
APA
Melkis, K., Wrońska, K., Antoniewska, N., Walczyńska, J., Kostrzewa, A., Szymczykowska, K., & Jakubczyk, K. (2026). Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review. Nutrients, 18(21), 3646. https://doi.org/10.3390/nu18213646
Vancouver
Melkis K, Wrońska K, Antoniewska N, Walczyńska J, Kostrzewa A, Szymczykowska K, et al. Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review. Nutrients. 2026;18(21):3646. doi:10.3390/nu18213646
BibTeX
@article{Melkis2026,
author = {Melkis, Klaudia and Wrońska, Karolina and Antoniewska, Natalia and Walczyńska, Joanna and Kostrzewa, Amelia and Szymczykowska, Kinga and Jakubczyk, Karolina},
title = {Edible and Medicinal Mushrooms in Metabolic Syndrome: From Mechanistic Plausibility to Clinical Evidence—A Narrative Review},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {21},
pages = {3646},
doi = {10.3390/nu18213646}
}
EUVIMED